# Phase 3 Study of QLG2198 in Haemodialysis Chinese Adult Subjects With Moderate-to-Severe Pruritus

> **NCT06446310** · PHASE3 · RECRUITING · sponsor: **Qilu Pharmaceutical (Hainan) Co., Ltd.** · enrollment: 194 (estimated)

## Conditions studied

- Uremic Pruritus

## Interventions

- **DRUG:** QLG2198
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT06446310
- **Lead sponsor:** Qilu Pharmaceutical (Hainan) Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-06-18
- **Primary completion:** 2025-02-21
- **Final completion:** 2025-08-03
- **Target enrollment:** 194 (ESTIMATED)
- **Last updated:** 2024-06-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06446310

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06446310, "Phase 3 Study of QLG2198 in Haemodialysis Chinese Adult Subjects With Moderate-to-Severe Pruritus". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT06446310. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*